Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer

DISEASE CHARACTERISTICS: * Diagnosis of metastatic colorectal cancer, meeting all of the following criteria: * Metachronous or synchronous liver metastases * Metastases potentially completely resectable * No requirement for resection combined with cryotherapy or radiofrequency ablation * Must have undergone complete resection (R0) of the primary tumor within the past 4 weeks * Measurable liver metastases * No evidence of extrahepatic disease * 1 or 2 resectable lung metastases allowed PATIENT CHARACTERISTICS: * WHO performance status 0-1 * Absolute neutrophil count \> 1,500/mm³ * Platelet count \> 100,000/mm³ * Hemoglobin \> 9 g/dL * WBC \> 3,000/mm³ * Creatinine \< 1.5 times upper limit of normal (ULN) * Bilirubin \< 1.5 times ULN * AST and ALT \< 5 times ULN * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No significant proteinuria (i.e., protein \> 500 mg/24-hour urine collection) * No known allergy to any of the study drugs (including excipients) or any related compound, including hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies * No bleeding diathesis or coagulopathy * No peripheral neuropathy \> grade 1 * No serious nonhealing wound, ulcer, or bone fracture * No clinically significant cardiovascular disease, including any of the following: * Uncontrolled hypertension * New York Heart Association class II-IV congestive heart failure * Unstable angina pectoris within the past 12 months * Peripheral vascular disease ≥ grade 2 * Serious cardiac arrhythmia requiring medication * Myocardial infarction within the past 12 months * Cerebrovascular accident or transient ischemic attack within the past 12 months * No symptomatic diverticulitis or known gastroduodenal ulceration * No significant traumatic injury within the past 4 weeks * No known alcohol or drug abuse * No psychological, familial, social, or geographical condition that would preclude study compliance * No other significant disease that would preclude study participation PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior chemotherapy for metastatic disease * At least 1 month since prior major surgical procedure or open biopsy * More than 30 days since prior participation in another clinical study * Prior adjuvant chemotherapy for primary cancer allowed provided the following criteria are met: * At least 12 months since prior oxaliplatin-containing adjuvant therapy * No persistent neuropathy * No prior therapy targeting the epidermal growth factor receptor or vascular endothelial growth factor (VEGF)/VEGF receptor * No concurrent regular use of acetylsalicylic acid (\> 325 mg/day) or other nonsteroidal anti-inflammatory drugs * No concurrent full-dose anticoagulation * No concurrent prophylactic hematopoietic growth factors * No concurrent allopurinol